Decreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer
Authors:
- Hanna KędzierskaHKHanna Kędzierska
- Piotr PopławskiPPPiotr Popławski
- Grażyna HoserGHGrażyna Hoser
- Beata RybickaBRBeata Rybicka
- Katarzyna RodzikKRKatarzyna Rodzik
- Elżbieta SokółESElżbieta Sokół
- Joanna BogusławskaJBJoanna Bogusławska
- Zbigniew TańskiZTZbigniew Tański
- Anna FogtmanAFAnna Fogtman
- Marta KoblowskaMKMarta Koblowska
- Agnieszka Piekiełko-WitkowskaAPAgnieszka Piekiełko-Witkowska
Open Access
- 28 September 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (10) , 1598
Abstract
Serine and arginine rich splicing factor 2(SRSF2) belongs to the serine/arginine (SR)-rich family of proteins that regulate alternative splicing. Previous studies suggested that SRSF2 can contribute to carcinogenic processes. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, highly aggressive and difficult to treat, mainly due to resistance to apoptosis. In this study we hypothesized that SRSF2 contributes to the regulation of apoptosis in ccRCC. Using tissue samples obtained from ccRCC patients, as well as independent validation on The Cancer Genome Atlas (TCGA) data, we demonstrate for the first time that expression of SRSF2 is decreased in ccRCC tumours when compared to non-tumorous control tissues. Furthermore, by employing a panel of ccRCC-derived cell lines with silenced SRSF2 expression and qPCR arrays we show that SRSF2 contributes not only to splicing patterns but also to expression of multiple apoptotic genes, including new SRSF2 targets: DIABLO, BIRC5/survivin, TRAIL, BIM, MCL1, TNFRSF9, TNFRSF1B, CRADD, BCL2L2, BCL2A1, and TP53. We also identified a new splice variant of CFLAR, an inhibitor of caspase activity. These changes culminate in diminished caspase-9 activity and inhibition of apoptosis. In summary, we show for the first time that decreased expression of SRSF2 in ccRCC contributes to protection of cancer cells viability.Keywords
Funding Information
- Narodowym Centrum Nauki (DEC-2012/05/B/NZ5/01541, 2014/13/B/NZ5/00283)
This publication has 60 references indexed in Scilit:
- DNA Methylation-regulated miR-193a-3p Dictates Resistance of Hepatocellular Carcinoma to 5-Fluorouracil via Repression of SRSF2 ExpressionJournal of Biological Chemistry, 2012
- Splicing factor SC35 promotes tau expression through stabilization of its mRNAFEBS Letters, 2011
- The SR protein family of splicing factors: master regulators of gene expressionBiochemical Journal, 2008
- ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2008
- The splicing factor SC35 has an active role in transcriptional elongationNature Structural & Molecular Biology, 2008
- Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosisBritish Journal of Cancer, 2008
- Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and SurvivinJournal of Biological Chemistry, 2007
- Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian OrganogenesisMolecular and Cellular Biology, 2007
- BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteinsJournal of Cell Biology, 2007
- TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potentialBritish Journal of Cancer, 2003